recombinant hCG
PreclinicalSmall molecule
recombinant hCG is one of 9 small molecule programs targeting CLE. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in CLE
#DrugCompanyPhaseTrials
1Zytiga
Johnson & JohnsonPhase 3
Zuragard
ZZurex Pharma, Inc.
Phase 2
Keto Acid
UUniversity Hospital, Clermont-Ferrand
Phase 3
Brethine
SanofiPreclinical
Povidine-Iodine
MMidAtlantic Retina
Phase 2
Pharmacokinetics
PfizerPhase 1
Clenbuterol
UUniversity of Copenhagen
Preclinical
Triptorelin Acetate
IpsenPreclinical
recombinant hCG
UUniversitair Ziekenhuis Brussel
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy1 trial
Pregnancy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for recombinant hCG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversitair Ziekenhuis Brussel